Health
100 Most Popular
Therapy

CRISPR

$35.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.27 (-6.00%) Today
-$0.57 (-1.60%) After Hours

Why Robinhood?

You can buy or sell CRISPR and other stocks, options, ETFs, and crypto commission-free!

About

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. Read More The company was founded by Rodger Novak, Emmanuelle Charpentier, and Shaun Patrick Foy in 2014 and is headquartered in Zug, Switzerland.

Employees
188
Headquarters
Zug, Zug
Founded
2014
Market Cap
1.85B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.09M
High Today
$38.00
Low Today
$35.20
Open Price
$37.57
Volume
375.49K
52 Week High
$73.90
52 Week Low
$22.22

Collections

Health
100 Most Popular
Therapy
Biotechnology
Medical
Technology
2016 IPO

News

ForbesMar 14

Call For CRISPR Moratorium Echoes Early Days Of Gene Therapy

A group of influential scientists have urged that clinical use of CRISPR be put on hold in the wake of the Chinese gene-edited baby debacle.

2,643
PR NewswireMar 12

University of California granted new CRISPR-Cas9 patent, extending its patent portfolio for genome editing

BERKELEY, Calif., March 12, 2019 /PRNewswire/ -- The University of California announced today that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent Number 10,227,611, covering use of single molecule RNA guides and Cas9 protein in any cell, thus creating efficient and effective ways for scientists to target and edit genes. This patent is co-owned by The Regents of the University of California, the University of Vienna, and Emmanuelle Charpentier. The CRISPR-Cas9 DNA-targeting technology, inve...

352
Simply Wall StMar 7

Is CRISPR Therapeutics AG (NASDAQ:CRSP) As Strong As Its Balance Sheet Indicates?

Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as CRISPR Therapeutics AG (NASDAQ:CRSP), with a market capitalization of US$2.0b, rarely draw their attention from the investing community.

1,336

Earnings

-$1.07
-$0.71
-$0.36
$0.00
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.